Goldman Sachs analyst Corinne Jenkins lowered the firm’s price target on Intra-Cellular to $74 from $77 and keeps a Neutral rating on the shares. The company beat on the top line in Q2 and raised its FY24 revenue view “modestly”, though when considering the consistent revenue growth vs. expense spend on the forward basis, the company will shift to profitability in 2026 at the earliest, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- Intra-Cellular Therapies Welcomes New CFO Sanjeev Narula
- Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer
- Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance
- Is ITCI a Buy, Before Earnings?
- Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast